Affordable Access

deepdyve-link
Publisher Website

The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing

Authors
  • Hu, Xuqiao1, 2
  • Zhou, Zhenru1
  • Li, Fei3
  • Xiao, Yang3
  • Wang, Zhaoyang1
  • Xu, Jinfeng1
  • Dong, Fajin1
  • Zheng, Hairong3
  • Yu, Rongmin2, 4, 5
  • 1 Department of Ultrasound, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China
  • 2 Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China
  • 3 Paul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, SZ University Town, Shenzhen, 518055, China
  • 4 Department of Pharmacology, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China
  • 5 Biotechnological Institute of Chinese Materia Medica, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China
Type
Published Article
Journal
Heliyon
Publisher
Elsevier
Publication Date
Mar 01, 2021
Volume
7
Issue
3
Identifiers
DOI: 10.1016/j.heliyon.2021.e06387
PMID: 33688584
PMCID: PMC7919521
Source
PubMed Central
Keywords
License
Unknown

Abstract

SARS-CoV-2; Drug screen and repurposing; Mall molecule microarray chip; Antiviral compounds.

Report this publication

Statistics

Seen <100 times